Skin biopsies and seed amplification assays (SAA) provide a sensitive and potentially quantitative method to detect alpha‐synuclein (a‐syn) aggregation in peripheral nerve fibers in Parkinson's disease (PD). Relating to the… Click to show full abstract
Skin biopsies and seed amplification assays (SAA) provide a sensitive and potentially quantitative method to detect alpha‐synuclein (a‐syn) aggregation in peripheral nerve fibers in Parkinson's disease (PD). Relating to the previously published hypothesis that PD may either originate in the peripheral (body‐first) or central (brain‐first) nervous system, we investigated whether patients with clinical features that have been reported to be associated with a suspected body‐first subtype of PD exhibit higher levels of a‐syn aggregation in dermal nerve fibers compared to those without these features. Patients with isolated REM sleep behavior disorder (iRBD) representing a suspected premotor stage of body‐first PD were studied in comparison to the PD cohort.
               
Click one of the above tabs to view related content.